对14岁以下轻度和无症状的Omicron感染儿童进行了回顾性分析:单中心研究
Jing Sun1, Haiyan Zhang1, Zhen Yang2
1Department of Pediatrics, Lanzhou Chengguan District People's Hospital, Lanzhou City, China.
Medicine
|February 16, 2024
概括
这项研究发现,老年儿童和接种疫苗剂量较少的儿童在感染Omicron BA.5.2后的病毒泄漏时间较长. 然而,大多数儿童的康复良好,表明预后良好.
科学领域:
- 儿科 儿科 儿科
- 传染性疾病 传染性疾病
- 病毒学 病毒学
背景情况:
- 有限的数据存在于Omicron BA.5.2亚变体在儿童中的传播.
- 与其他Omicron亚型相比,Omicron BA.5.2的传播能力增加.
研究的目的:
- 在儿童中分析Omicron BA.5.2变体感染的临床特征.
- 在儿科病例中识别影响感染和病毒分泌的因素.
主要方法:
- 从移动客医院回顾收集轻度和无症状的Omicron BA.5.2感染儿童 (<14岁) (2022年10月至12月).
- 对临床表现,症状持续时间和核酸负转化时间的分析.
- 单变量和多变量分析以确定影响因素.
主要成果:
- 包括741名儿童 (57.2%男孩);22.7%无症状,77.3%轻度病例.
- 上呼吸道感染占主导地位;发烧 (80.7%) 和咳 (52.5%) 是常见的症状.
- 平均症状缓解时间为3.76天;平均核酸负转化时间为12.3天.
- 高龄与较长的负转换时间相关;疫苗接种与转换时间负相关.
结论:
- 儿童的奥米克朗BA.5.2感染呈现出轻度症状,主要是上呼吸道,有很好的康复前景.
- 年龄和疫苗接种状况是影响儿科Omicron BA.5.2感染病毒分泌持续时间的重要危险因素.
相关概念视频
Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Investigation of Disease Outbreaks
Multistate foodborne outbreaks pose significant public health risks and require meticulous investigation to identify sources and implement control measures. The Centers for Disease Control and Prevention (CDC) utilizes a dynamic seven-step process for these investigations, integrating data from laboratories, interviews, and environmental assessments to protect public health.Outbreak Detection: The detection of multistate outbreaks typically begins with PulseNet, the CDC's national laboratory...


